Association of ABO Polymorphisms and Pancreatic Cancer/ Cardiocerebrovascular Disease: a Meta-analysis.

CURRENT STATUS: UNDER REVIEW

Yanxia Li
Tianjin Tumor Hospital

Luyang Liu
Tianjin Tumor Hospital

Yubei Huang
Tianjin Tumor Hospital

Hong Zheng
Tianjin Tumor Hospital

Lian Li ✉ lilian@tmu.edu.cn
Tianjin Medical University Cancer Institute and Hospital
Corresponding Author
ORCiD: 0000-0001-6963-558X

DOI: 10.21203/rs.2.23107/v3

SUBJECT AREAS
Medical Genetics

KEYWORDS
ABO gene polymorphism, rs505922, rs657152, Cardiocerebrovascular diseases, Cancer, Meta-analysis
Abstract

Background: ABO gene polymorphisms have been reported to be associated with the risk of multiple cancers and cardiocerebrovascular disease s. However, the results remained controversial. In this study, we conducted a systematic review and meta-analysis to clarify the association between two SNPs (rs505922 and rs657152) in ABO gene and cancers/ cardiocerebrovascular disease s. Method: All eligible case-control studies come from PubMed, Embase and Web of Science up to Jan. 1, 2019. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the corresponding associations. Sensitivity analysis, publication bias assessment, and heterogeneity test were performed using STATA 12.0. Results: A total of nineteen articles involving twenty-two case-control populations were included according to inclusion and exclusion criteria. Twelve populations (20,820 cases and 27,837 controls) were used to evaluate the relationship between rs505922 and overall cancers and nine populations (22,275 cases and 71,549 controls) were included to assess the association between rs505922 and cardiocerebrovascular diseases. The results showed a significant association between the rs505922 polymorphism and cancers (CvsT: OR=1.13, 95%CI=1.05-1.22, P =0.001), and cardiocerebrovascular diseases (OR=1.36, 95%CI=1.19-1.57, P <0.001). Five populations (8,660 cases and 10,618 controls) were included to evaluate association between rs657152 and cancers and five populations (8,105 cases and 6,712 controls) were included to estimate the relationship between rs657152 and cardiocerebrovascular diseases. The result of meta-analysis reveals that rs657152 was significantly associated with cancers (OR=1.18, 95%CI=1.13-1.23, P <0.001) and cardiocerebrovascular diseases (OR=1.54, 95%CI=1.24-1.92, P <0.001). Conclusion: Our study suggested that ABO polymorphisms might serve as a risk factor of pancreatic cancers and cardiocerebrovascular diseases.
Background

The incidence of cancer and cardiovascular disease increases with age and both of them are related to inflammation and thrombosis et al [1, 2]. Epidemiological studies have demonstrated that ABO blood groups were associated with several chronic inflammation related diseases, including cancers and cardiocerebrovascular diseases [3-5]. Although a possible common pathogenic mechanism involving the von Willebrand factor between ABO blood group system and cancer/cardiovascular disease has been discussed [6], the relationship between histoblood group antigens and inflammation related diseases remains unknown and the regulatory mechanisms underlying ABO expression was still unclear.

The ABO blood group system is composed of complex carbohydrate structures that are biosynthesized by A- and B- transferases encoded by ABO gene. ABO gene is located at the 9q34 region of the chromosome and encodes enzyme glycosyltransferase with two main allele (A and B), a specific glycosyltransferase catalyzes the covalent attachment of N-acetylgalactosamine or D-galactose to a common precursor side chain (H determinant), ultimately to an A or B antigen [7]. Several SNPs in the ABO gene have been suggested to be associated with increased risks to the development of cancer and cardiocerebrovascular disease by genome-wide association studies (GWAS) and candidate gene studies [8-11]. Particularly, the most widely investigated SNPs of the ABO gene were rs505922 and rs657152 [12-15]. Meta-analysis that evaluated the relationship between rs505922 SNP and overall cancer have already been reported by Duan et al [16] four years ago. However, two new studies of cancer risk [11, 17] and several studies of cardiocerebrovascular diseases risk [14, 15, 18-21] have been reported in recent years and the relationship between SNPs in ABO gene and cancer/cardiocerebrovascular diseases risk was still unclear. Here, we have performed a meta-analysis including the
newly published studies and evaluated the associations between polymorphisms of ABO gene and cancers/cardiocerebrovascular diseases.

Methods

Search strategy

Two investigators (Yanxia Li and Luyang Liu) performed a systematic literature search in three databases: PubMed, Web of Science and Embase to identify relevant articles published from the initial to Jan 1, 2019. The following search terms were used either separately or in combination: "SNP" "Polymorphism" and "Polymorphism, Single Nucleotide" "rs505922, rs657152" and "neoplasms" "carcinoma" "tumor" "cancer" and "vascular diasease" "cardiovascular disease" "cardiac-cerebral disease" and "ABO Blood-Group System" "Lewis Blood-Group System" "ABO". Once suitable studies were singled out from the search results, other potentially relevant articles were identified by cross-references within eligible studies. The references of each identified articles were also searched manually to identify eligible studies.

Selection criteria

The inclusion criteria for these studies were as follows: 1) Studies evaluating the association between rs505922/rs657152 variants and cancers or cardiocerebrovascular diseases; 2) The study design was a case-control study in humans (both hospital based case-control study and cohort based nested case-control study were included); 3) Researches containing universal allele and genotype data; 4) Studies written in English. The exclusion criteria were as follows: 1) Studies did not describe the association of ABO gene polymorphism with cancers or cardiocerebrovascular diseases; 2) Systematic reviews or articles focusing on animals; 3) Studies that did not provide usable data for meta-analysis.

Data extraction and quality assessment
Two investigators (Yanxia Li and Luyang Liu) independently extract data and verify the accuracy of the data. The following information was extracted from each article: first authors, publication years, ethnicity, cancer types, and study design (hospital- or population-based), sample size of subject, number of cases and controls for each genotype, OR and 95% CI in allele model. When there was no data of allele model in the article, we calculated the data of allele model by using the formula. To assess the quality of the study, we used the Newcastle-Ottawa Scale (NOS) with a nine-star system [22]; this scale assesses the quality of cohort and case-control studies. The highest score of NOS is nine stars: four stars for the selection process, three stars for exposure/outcome, and two stars for comparability. A score of seven or above was considered to be high-quality study.

**Statistical analysis**

We used odds ratios (ORs) and 95% confidence intervals (CIs) to assess the relationship between each SNP and the risk of cancers or cardiocerebrovascular diseases. The association was examined using allele model. The significance of the pooled OR was determined by the Z-test. Subgroup analyses were conducted according to cancer types, ethnic groups and sources of controls. Heterogeneity between articles was identified with Q-test and I² index, I² values of >50% indicated heterogeneity among studies. If there was heterogeneity (I²>50%) between studies, we used a random effect model (DerSimonian-Laird method), otherwise we used a fixed effect model (Mantel-Haenszel method). Sensitivity analysis was performed to assess the effects of individual studies on pooled results and the stability of the results. We used Egger’s and Begg’s test to evaluate the publication bias, with a \( P>0.05 \) considered to be evidence for no potential publication bias. Trim and fill method was also applied in detecting publication bias. All the tests were two-sided and \( P<0.05 \) was considered to be statistically significant. Stata version 12.0 SE
was applied to carry out the statistical analysis.

Results

Study characteristics

After retrieving the database, a total of 545 records [PubMed (n = 146), Web of Science (n=149), EMBASE (n=250)] were obtained. According to the inclusion/exclusion criteria, nineteen articles were included and the detailed flowchart of study selection process was presented in Fig. 1. Twelve studies reported the association between rs505922 and cancer risk [11-13, 17, 23-30] and five studies reported the association between rs657152 and cancer risk [12, 13, 17, 30, 31]. Six studies included nine populations reported the association of cardiocerebrovascular diseases with rs505922 [14, 15, 18-21], and three studies with rs657152 [14, 15, 20]. Detailed characteristics and genotype distribution of included articles for two SNPs were shown in Table 1 and Table 2. In addition, seven additional SNPs which had strong linkage disequilibrium (LD) with rs525922 were reported to be associated with cardiocerebrovascular disease (Table S1) [8, 14, 15, 21, 32-35]. However, the association between these SNPs with cancer risk has not been reported. According to the source of control groups, nine studies were population-based (PB), six studies were hospital-based (HB), and three studies were population and hospital-based(PB/HB) control. For SNP rs505922, ten studies were from Caucasian population[11, 13, 15, 19, 20, 23-26, 29], four studies were from Asian [12, 18, 21, 27] and four studies were from Mixed and African [14, 17, 28, 30]. For the rs657152 polymorphism, there were four studies originating from Caucasian[13, 15, 20, 31], and four studies were from Asian and African or Mixed population [12, 14, 17, 30]. Each study was scored based on the Newcastle-Ottawa Scale (NOS) and detailed study qualities were presented in Table S2 and Table S3.

Meta-analysis of rs505922 polymorphism
Meta-analysis was conducted to estimate the associations between rs505922 and cancer risk (Fig. 2a; Table S4) in 20,820 cancer cases and 27,837 controls. The rs505922 polymorphism was significantly associated with an increased cancers risk in the allele model (OR=1.13, 95%CI=1.05-1.22, \(P=0.001\)). Subgroup analysis was conducted based on ethnicity, type of cancer, and source of control. The association between rs505922 and cancer risk was identified in Asian population subgroup (OR=1.27, 95%CI=1.10-1.48, \(P=0.002\)), Mixed population subgroup (OR=1.22, 95%CI=1.17-1.27, \(P<0.001\), Pancreatic cancers subgroup (OR=1.23, 95%CI=1.16-1.31, \(P<0.001\), and Hospital based control groups (OR=1.30, 95%CI=1.12-1.51, \(P=0.003\)) (Table S5; Fig. S1). However, no significant association was observed in Caucasian population (OR=1.05, 95%CI=0.97-1.13, \(P=0.232\)). Sensitivity analyses were conducted by omitting each individual article to measure its specific effect on the pooled ORs (Fig. S2a). Sensitivity analysis plot indicated that no single study significantly affected the combined OR of SNP loci. Because of the heterogeneity of the research, we use the random effect model (allele model: \(I^2=81.8\%) (Table S4). No significant publication bias was observed in any studies of SNPs (Fig. 4a; Table S4). After the applying the trim and fill method, there is no change in the OR value after the combination, also indicating that the original result is stable (Fig. S3).

We also performed a meta-analysis to evaluate the association between rs505922 SNP and cardiocerebrovascular diseases (Fig. 2b; Table S4). The rs505922 SNP was significantly associated with an increased cardiocerebrovascular diseases risk in the allele model (C/T: OR=1.36, 95%CI=1.19-1.57, \(P<0.001\)). Subgroup analysis indicated that rs505922 was associated with a significantly higher risk of cardiocerebrovascular diseases in Caucasian population subgroup (OR=1.39, 95%CI=1.19-1.64, \(P<0.001\), allele model), African population subgroup (OR=1.52, 95%CI=1.18-1.96, \(P=0.001\), Hospital based control (OR=1.14, 95%CI=1.05-1.23, \(P=0.003\)) and Population based control (OR=1.54,
95% Cl=1.18-2.02, \( P=0.002 \) (Table S5; Fig. S4). However, no significant association was observed in Asian subgroup (OR=1.21, 95% Cl=0.67-2.19, \( P=0.524 \) (Table S5; Fig. S4).

Sensitivity analysis showed the results of this study were stable (Fig. S2b). There was no significant publication bias among the enrolled studies in Begg’s and Egger’s test (Fig. 4b; Table S4). After applying the trim and fill method, no new literature has been added, indicating that the result is stable (Fig. S5).

**Meta-analysis of rs657152 polymorphisms**

Five studies reported the association between rs657152 and cancers risk. Our results showed that rs657152 was significantly associated with increased cancers risk in allele model (OR=1.18, 95% CI=1.13-1.23, \( P<0.001 \) (Fig. 3a; Table S4). Sensitivity analysis revealed no significant influence on the pooled OR by any individual study (Fig. S6a). We conducted Begg’s and Egger’s tests to assess the publication bias for these studies and no evidence of publication bias was detected among the enrolled studies (Fig. 4c; Table S4). According to the results of trim and fill method, the result was stable (Fig. S7).

We also evaluated the relationship between rs657152 and cardiocerebrovascular diseases. A significant association between rs657152 and cardiocerebrovascular diseases under allele model were observed (OR=1.54, 95% CI=1.24-1.92, \( P<0.001 \) (Fig. 3b; Table S4). Sensitivity analysis suggested that there was no significant change in the overall outcomes after removing any of the studies (Fig. S6b). The Begg’s and Egger’s tests also showed that no meaningful publication bias were found (Fig. 4d; Table S4). The result of the trim and fill method proves that the result was stable (Fig. S8).

**Discussion**

In this study, we conducted a meta-analysis to clarify the relationship between ABO SNPs (rs505922 and rs657152) and cancer/cardiocerebrovascular diseases risk. Our results showed that these two SNPs were associated with pancreatic cancer risk and also
increased the risk of cardiocerebrovascular diseases.

Regarding to rs505922 SNP, our results showed that the variant type of rs505922 could increase the risk of overall cancer, suggesting a potential predictive ability of this SNP for cancer risk. When we conducted a subgroup analysis of rs505922 based on cancer sites and ethnicity, we found that there was no significant association between rs505922 and Non-pancreatic cancer subgroup or Caucasian subgroup. This result may be due to heterogeneity of cancer types or insufficient statistical power. Therefore, further studies with large samples size are warrant to evaluate the association between the rs505922 polymorphisms in Non-pancreatic cancers. On the other side, our data also showed that rs505922 was associated with cardiocerebrovascular diseases. In subgroup analysis, we found that there was no association between rs505922 and cardiocerebrovascular diseases in Asian subgroup. Only two studies with small population were included in this analysis, further studies are needed in Asian population. The SNP is located in the first intron region of ABO gene, the protective T allele of rs505922 is in complete linkage disequilibrium ($r^2=1.0$) with the O allele, is marks of O allele. However, the regulatory mechanism underlying the expression of histoblood group antigens was unclear.

For rs657152, our study demonstrated that this SNP was associated with cancer/ cardiocerebrovascular diseases risk. However, only eight studies [12-15, 17, 20, 30, 31] were reported and most of studies were conducted in Caucasian population. Therefore, more studies with different ethnic background and larger sample size are needed in the future. Rs657152 is located in the intron area of ABO, the possible function has not been revealed yet. Rs657152 has been found to be associated with several biological molecule, including LDL cholesterol [36], liver derived alkaline phosphatas [37], and IL-6 [38]. This implied that rs657152 may affect the occurrence and development of disease by influencing these biological molecule. Further subsequent functional studies are warrant.
The underlying mechanism for the relationship between ABO blood group and cancer risk is still poorly understood [39]. It is reported that blood type may affect the progression and expansion of malignant tumors by altering the systemic inflammatory response [40]. Recent studies reported an association between polymorphisms at the ABO gene locus and circulating levels of tumour necrosis factor-alpha [41], soluble intercellular adhesion molecule (ICAM)-1 [42, 43], E-selectin [44, 45], and P-selectin [43]. These adhesion molecules were important mediators of chronic inflammation and immune cell recruitment [46]. They may provide a biological basis for the postulated influence of ABO on cancer survival, by linking ABO blood group and tumour initiation and spread [39]. In addition, some researches have shown that the structure of certain tumor antigens was similar to the structure of antigens of ABO blood group system. Smith and Prieto [47] suggested the Forssmann antigen which predominant in stomach and colon tumors, was almost structurally identical to the A antigen determinant. Blood group A carrier may have diminished tumor immune response due to reduced ability to recognize and attack tumor cells [48].

There was some evidence linking ABO blood group and cardiocerebrovascular diseases. Jenkins, P.V. et al. reported an association between ABO blood types and von Willebrand factor (vWF) and factor VIII (FVIII), both of which play crucial roles in the coagulation pathway [49]. Higher levels of vWF and FVIII has been observed in non-O blood type than O blood type [50]. Therefore, type O blood may be a risk factor for bleeding [51]. In addition, the non-O blood group has been shown to be correlated with higher total cholesterol and LDL-C levels [52], and the latest study proposed that approximately 10% of the effect of ABO blood group on coronary artery disease (CAD) susceptibility was mediated by plasma cholesterol levels [53].

Limitations in this study should be mentioned. First, the studies included in our meta-
analysis were limited to published reports and English language studies. Unpublished reports or those published in non-English language studies were not included in the analysis. It would limit our sample size and publication bias might be exist. Second, both of the hospital based and population based case-control studies were included in our study. Therefore, selection bias would be exist compared to the meta-analysis only included population based case-control studies. Third, the limited number of published studies may influence the reliability of our results. Finally, the lack of original data limited further evaluations of the potential gene-gene and gene-environment interactions.

Conclusion

In summary, the results of our meta-analysis revealed that rs505922 and rs657152 were correlated with an increased pancreatic cancers risk. Due to most of the studies were conducted in pancreatic cancer type and Caucasian populations, further studies in multiple cancer types and multiple ethnic populations are needed. In addition, our meta-analysis also revealed that rs505922 and rs657152 associated with cardiocerebrovascular diseases. However, owing to limited number of studies, further studies with larger samples size are warrant. This study can provide clues for further exploration of novel biomarkers with cancer/cardiocerebrovascular early-warning function.

Abbreviations

PB: population based, HB: hospital based, NOS: Newcastle-Ottawa Scale.

Declarations

Ethics approval and consent to participate:

Not applicable.

Consent for publication:

Not applicable.
Availability of data and material:
Not applicable.

Competing interests:
The authors declare no conflicts of interest.

Funding:
This work was supported by the National Natural Science Foundation of China (81973113, 81320108022, 81470153, and 81502877), Tianjin Science and Technology Committee Foundation (18YFZCSY00520 and 16JCYBJC26600), the National Key Research and Development Program of China (2016YFC1302703).
The funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Author’ Contributions:
Study conception and design: LL and HZ. Acquisition, analysis, or interpretation of data: YXL and LYL. Statistical analysis: YXL and YBH. Drafting of the manuscript: YXL and LYL.
Administrative, technical, or material support: HZ. Study supervision: LL and HZ. All authors have read and approved the final version of manuscript.

Acknowledgements:
Not applicable.

References
1. Falanga A, Russo L, Milesi V et al: Mechanisms and risk factors of thrombosis in cancer. *Crit Rev Oncol Hematol* 2017, 118:79-83.
2. Zhang X, Meng X, Chen Y et al: The Biology of Aging and Cancer: Frailty, Inflammation, and Immunity. *Cancer J* 2017, 23(4):201-205.
3. Zhang BL, He N, Huang YB et al: ABO blood groups and risk of cancer: a systematic review and meta-analysis. *Asian Pac J Cancer Prev* 2014,
13

4. Zu B, You G, Fu Q et al: Association between ABO Blood Group and Risk of Congenital Heart Disease: A 6-year large cohort study. Sci Rep 2017, 7:42804.

5. Vasan SK, Rostgaard K, Majeed A et al: ABO Blood Group and Risk of Thromboembolic and Arterial Disease: A Study of 1.5 Million Blood Donors. Circulation 2016, 133(15):1449-1457; discussion 1457.

6. Franchini M, Lippi G: The intriguing relationship between the ABO blood group, cardiovascular disease, and cancer. BMC Med 2015, 13:7.

7. Yamamoto F, Clausen H, White T et al: Molecular genetic basis of the histo-blood group ABO system. Nature 1990, 345(6272):229-233.

8. Ling X, Zheng Y, Tao J et al: Association study of polymorphisms in the ABO gene with ischemic stroke in the Chinese population. BMC Neurology 2016, 16:146.

9. Heit JA, Armasu SM, Asmann YW et al: A genome-wide association study of venous thromboembolism identifies risk variants in chromosomes 1q24.2 and 9q. J Thromb Haemost 2012, 10(8):1521-1531.

10. Gao M, Tang H, Zheng X et al: Association analysis of GWAS and candidate gene loci in a Chinese population with coronary heart disease. Int J Clin Exp Med 2015, 8(5):7497-7506.

11. Markt SC, Shui IM, Unger RH et al: ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3). Prostate 2015, 75(15): 1677-1681.

12. Xu H-L, Cheng J-R, Zhang W et al: Re-evaluation of ABO gene polymorphisms detected in a genome-wide association study and risk of pancreatic ductal adenocarcinoma in a Chinese population. Chinese Journal of Cancer 2014,
13. Duell EJ, Bonet C, Munoz X et al: Variation at ABO histo-blood group and FUT loci and diffuse and intestinal gastric cancer risk in a European population. *Int J Cancer* 2015, **136**(4):880-893.

14. Hernandez W, Gamazon ER, Smithberger E et al: Novel genetic predictors of venous thromboembolism risk in African Americans. *Blood* 2016, **127**(15):1923-1929.

15. Reilly MP, Li M, He J et al: Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. *Lancet* 2011, **377**(9763):383-392.

16. Duan YF, Zhu F, Li XD et al: Association between ABO gene polymorphism (rs505922) and cancer risk: a meta-analysis. *Tumour Biol* 2015, **36**(7):5081-5087.

17. Li D, Duell EJ, Yu K et al: Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. *Carcinogenesis* 2012, **33**(7):1384-1390.

18. Zhang H, Zhang Z, Zhang J et al: Fine-mapping of ABO gene identifies two novel SNPs associated with large artery atherosclerotic stroke in a Chinese han population. *Mol Neurobiol* 2017, **54**(3):2107-2113.

19. Williams FM, Carter AM, Hysi PG et al: Ischemic stroke is associated with the ABO locus: the EuroCLOT study. *Ann Neurol* 2013, **73**(1):16-31.

20. Tregouet DA, Heath S, Saut N et al: Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. *Blood* 2009, **113**:5298-5303.
21. Li H, Cai Y, Xu AD: Association study of polymorphisms in the ABO gene and their gene-gene interactions with ischemic stroke in Chinese population. *J Clin Lab Anal* 2018, **32**(4):e22329.

22. Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010, **25**(9):603-605.

23. Krawczyk M, Mihalache F, Hoblinger A et al: Pancreatic cancer risk variant ABO rs505922 in patients with cholangiocarcinoma. *World J Gastroenterol* 2011, **17**(41):4640-4642.

24. Gates MA, Xu M, Chen WY et al: ABO blood group and breast cancer incidence and survival. *Int J Cancer* 2012, **130**(9):2129-2137.

25. Rizzato C, Campa D, Pezzilli R et al: ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium. *Oncol Rep* 2013, **29**(4):1637-1644.

26. Poole EM, Gates MA, High BA et al: ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium. *Cancer Causes Control* 2012, **23**(11):1805-1810.

27. Nakao M, Matsuo K, Hosono S et al: ABO blood group alleles and the risk of pancreatic cancer in a Japanese population. *Cancer Science* 2011, **102**(5):1076-1080.

28. Wolpin BM, Kraft P, Gross M et al: Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. *Cancer Res* 2010, **70**(3):1015-1023.

29. Willis JA, Olson SH, Orlow I et al: A replication study and genome-wide scan of single-nucleotide polymorphisms associated with pancreatic cancer risk and
overall survival. Clin Cancer Res 2012, 18(14):3942-3951.

30. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ et al: **Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer.** Nature genetics 2009, 41(9):986-990.

31. Rizzato C, Campa D, Giese N et al: **Pancreatic cancer susceptibility loci and their role in survival.** PLoS One 2011, 6(11):e27921.

32. Hinds DA, Buil A, Ziemek D et al: **Genome-wide association analysis of self-reported events in 6135 individuals and 252 827 controls identifies 8 loci associated with thrombosis.** Hum Mol Genet 2016, 25(9):1867-1874.

33. Germain M, Chasman DI, de Haan H et al: **Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism.** Am J Hum Genet 2015, 96(4):532-542.

34. Heit JA, Cunningham JM, Petterson TM et al: **Genetic variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways as risk factors for venous thromboembolism.** J Thromb Haemost 2011, 9(6):1133-1142.

35. Bruzelius M, Strawbridge RJ, Tregouet DA et al: **Influence of coronary artery disease-associated genetic variants on risk of venous thromboembolism.** Thromb Res 2014, 134(2):426-432.

36. Teupser D, Baber R, Ceglarek U et al: **Genetic regulation of serum phytosterol levels and risk of coronary artery disease.** Circ Cardiovasc Genet 2010, 3(4):331-339.

37. Yuan X, Waterworth D, Perry JRB et al: **Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.** American Journal of Human Genetics 2008, 83(4):520-528.
38. Naitza S, Porcu E, Steri M et al: A genome-wide association scan on the levels of markers of inflammation in Sardinians reveals associations that underpin its complex regulation. PLoS Genetics 2012, 8(1):e1002480.

39. Franchini M, Favaloro EJ, Targher G et al: ABO blood group, hypercoagulability, and cardiovascular and cancer risk. Crit Rev Clin Lab Sci 2012, 49(4):137-149.

40. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010, 140:883-899.

41. Melzer D, Perry JR, Hernandez D et al: A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet 2008, 4(5):e1000072.

42. Pare G, Chasman DI, Kellogg M et al: Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women. PLoS Genet 2008, 4(7):e1000118.

43. Barbalic M, Dupuis J, Dehghan A et al: Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet 2010, 19(9):1863-1872.

44. Paterson AD, Lopes-Virella MF, Waggott D et al: Genome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin. Arterioscler Thromb Vasc Biol 2009, 29(11):1958-1967.

45. Qi L, Cornelis MC, Kraft P et al: Genetic variants in ABO blood group region, plasma soluble E-selectin levels and risk of type 2 diabetes. Hum Mol Genet 2010, 19(9):1856-1862.

46. Franchini M, Liumbruno GM, Lippi G: The prognostic value of ABO blood group in cancer patients. Blood Transfus 2016, 14(5):434-440.

47. Smith DF, Prieto PA: Forssmann antigen. In: Roitt IM, Delves PH (eds).
48. S R Yuzhalin AE, Kutikhin AG: **ABO and Rh blood groups in relation to ovarian, endometrial and cervical cancer risk among the population of South-East Siberia.** *Asian Pac J Cancer Prev* 2012, **13**(10):5091-5096.

49. Jenkins PV, O'Donnell JS: **ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?** *Transfusion* 2006, **46**(10):1836-1844.

50. Gill JC, Endres-Brooks J, Bauer PJ et al: **The effect of ABO blood group on the diagnosis of von Willebrand disease.** *Blood* 1987, **69**(6):1691-1695.

51. Dentali F, Sironi AP, Ageno W et al: **Relationship between ABO blood group and hemorrhage: a systematic literature review and meta-analysis.** *Semin Thromb Hemost* 2013, **39**(1):72-82.

52. Silbernagel G, Chapman MJ, Genser B et al: **High intestinal cholesterol absorption is associated with cardiovascular disease and risk alleles in ABCG8 and ABO: evidence from the LURIC and YFS cohorts and from a meta-analysis.** *J Am Coll Cardiol* 2013, **62**(4):291-299.

53. Chen Y, Chen C, Ke X et al: **Analysis of circulating cholesterol levels as a mediator of an association between ABO blood group and coronary heart disease.** *Circ Cardiovasc Genet* 2014, **7**(1):43-48.

**Tables**

Table1. Characteristics of the studies included in the meta-analysis of the association between SNPs and cancers
| SNP loci | Year | First author | Ethnicity | Cancer/disease | Control* | Sample size (case/control) |
|----------|------|--------------|-----------|----------------|----------|--------------------------|
| rs505922 | 2015 | SC. Markt    | Caucasian | Prostate cancer | -        | 2774/4443                |
|          | 2015 | E. Duell    | Caucasian | Gastric cancer  | PB       | 365/1284                 |
|          | 2014 | H. Xu       | Asian     | Pancreatic cancer | PB   | 256/548                  |
|          | 2013 | C. Rizzato  | Caucasian | Pancreatic cancer | HB/PB | 1028/2257                |
|          | 2012 | E. Poole    | Caucasian | Ovarian cancer  | HB/PB    | 5233/6838                |
|          | 2012 | D. Li       | Mixed     | Pancreatic cancer | HB    | 3851/3934                |
|          | 2012 | J. Willis   | Caucasian | Pancreatic cancer | HB    | 385/149                  |
|          | 2012 | M. Gates    | Caucasian | Breast cancer   | PB       | 1138/1090                |
|          | 2011 | M. Krawczyk | Caucasian | Cholangiocarcinoma | PB | 180/350                  |
|          | 2011 | M. Nakao    | Asian     | Pancreatic cancer | HB    | 185/1465                 |
|          | 2010 | B. Wolpin   | Mixed     | Pancreatic cancer | PB   | 1534/1583                |
|          | 2009 | L. Amundadottir | Mixed | Pancreatic cancer | HB/PB  | 3891/3932                |
| rs657152 | 2015 | E. Duell    | Caucasian | Gastric cancer  | PB       | 365/1284                 |
|          | 2014 | H. Xu       | Asian     | Pancreatic cancer | PB   | 256/548                  |
|          | 2012 | D. Li       | Caucasian | Pancreatic cancer | HB    | 3851/3934                |
|          | 2011 | C. Rizzato  | Caucasian | Pancreatic cancer | PB    | 686/1255                 |
|          | 2009 | L. Amundadottir | Mixed | Pancreatic cancer | HB/PB  | 3502/3597                |

*PB: population based control, HB: hospital based control; †Hom: homozygous, Het: heterozygote

Table 2 Characteristics of the studies included in the meta-analysis of the association between SNPs and cardiocerebrovascular diseases.
| SNP loci | Year | First author | Ethnicity | Cancer/disease | Control* | Sample size (case-control) |
|---------|------|--------------|-----------|----------------|----------|---------------------------|
| rs505922 | 2017 | H. Li        | Asian     | Ischemic stroke | PB       | 991/1002                   |
|         | 2017 | H. Zhang     | Asian     | Large artery atherosclerotic stroke | PB       | 644/642                   |
|         | 2016 | W. Hernandez | African   | Venous Thrombosis | HB       | 146 /432                  |
|         | 2013 | FM.Williams-a† | Caucasian | Ischemic stroke | HB       | 4092/8383                 |
|         | 2013 | FM.Williams-b† | Caucasian | Ischemic stroke | HB       | 8443 /5481                |
|         | 2011 | MP. Reilly   | Caucasian | Myocardial infarction | HB       | 5783/3644                 |
|         | 2009 | DA.Trégouet-a§ | Caucasian | Venous thromboembolism | PB       | 419/1228                  |
|         | 2009 | DA.Trégouet-b§ | Caucasian | Venous thromboembolism | PB       | 1150/801                  |
|         | 2009 | DA.Trégouet-c§ | Caucasian | Venous thromboembolism | PB       | 607/607                   |
| rs657152 | 2016 | W. Hernandez | African   | Venous Thrombosis | HB       | 146 /432                  |
|         | 2011 | MP. Reilly   | Caucasian | Myocardial infarction | HB       | 5783/3644                 |
|         | 2009 | DA.Trégouet-a§ | Caucasian | Venous thromboembolism | PB       | 419/1228                  |
|         | 2009 | DA.Trégouet-b§ | Caucasian | Venous thromboembolism | PB       | 1150/801                  |
|         | 2009 | DA.Trégouet-c§ | Caucasian | Venous thromboembolism | PB       | 607/607                   |

*PB: population based control, HB: hospital based control; †Hom: homozygous, Het: heterozygote; a† represent the MOonica Risk, Genetics, Archiving and Monograph(MORGAM) and the Wellcome Trust Case Control Consortium 2(WTCCC2) population, b† represent MetaStroke population; a§ represent GWAS population from 4 different French centers, b§ represent MARseille THrombosis Association study (MARTHA) population, c§ represent FARIVE that is a multicenter case-control study
Figures
Fig. 1

Total articles from PubMed, EMBASE and Web of Science (N=545)

Number of articles remained after removing duplicate articles (N=253)

Excluded by reading abstracts:
- Not about ABO SNPs
- Not related to cancer
- Not related to cardiocerebrovascular diseases
- Other research types: review, meta-analysis
- Not human research (N=163)

Full-text articles reviewed (N=90)

Excluded by reading the full text:
- Not case-control studies
- No detail data (N=71)

Studies included (N=19)
Figure 1

Flow chart of the study selection process.
### Figure 2

**A**

| Study ID | ES (95% CI) | % Weight |
|----------|-------------|----------|
| SC. Ma (2015) | 0.90 (0.80, 1.02) | 10.91 |
| E. Day (2015) | 1.00 (0.80, 1.26) | 7.24 |
| H. Xie (2014) | 1.24 (1.00, 1.53) | 6.01 |
| C. Ricciotti (2013) | 1.13 (1.01, 1.26) | 9.62 |
| E. Pa ready (2012) | 1.02 (0.97, 1.08) | 11.30 |
| M. Gak (2012) | 1.02 (0.90, 1.15) | 8.98 |
| M. Kowczynski (2011) | 0.97 (0.74, 1.27) | 4.60 |
| M. Nihans (2011) | 1.31 (1.00, 1.63) | 5.94 |
| B. Wollnik (2010) | 1.29 (1.10, 1.53) | 9.79 |
| L. Amundstedt (2009) | 1.20 (1.13, 1.29) | 11.05 |
| D. L. (2012) | 1.21 (1.13, 1.30) | 10.90 |
| J. Wilking (2012) | 1.05 (1.20, 1.26) | 5.68 |
| Overall (I-squared = 81.8%, p = 0.000) | 1.13 (1.04, 1.22) | 100.09 |

**B**

| Study ID | OR (95% CI) | % Weight |
|----------|-------------|----------|
| H. Li (2017) | 1.84 (1.41, 2.40) | 10.95 |
| H. Zhang (2017) | 0.46 (0.77, 1.65) | 10.82 |
| D. A. Grigore (2009) | 2.01 (1.71, 2.36) | 10.75 |
| DA. Trigge (2009) | 1.79 (1.57, 2.04) | 11.25 |
| DA. Trigge (2009) | 1.86 (1.41, 2.45) | 10.85 |
| W. Hernandez (2016) | 1.52 (1.26, 2.00) | 6.89 |
| F. Williams (2013) | 1.08 (1.01, 1.17) | 12.21 |
| F. Williams (2013) | 1.67 (1.03, 1.14) | 12.30 |
| M. Raly (2011) | 1.20 (1.13, 1.28) | 12.19 |
| Overall (I-squared = 50.3%, p = 0.000) | 1.30 (1.19, 1.47) | 100.09 |
Forest plot of the relationship between rs505922 polymorphisms and cancer (a) and cardiocerebrovascular disease (b) risk (allele model and random-effect model). The circle and horizontal lines correspond to OR and 95% CI and the area of the squares reflects the weight of individual studies included in the meta-analysis. The diamond represents the pooled ORs and 95% CI. The dotted red line represents the total OR value.
Fig. 3

A

| Study ID   | ES (95% CI)   | % Weight |
|------------|---------------|----------|
| H. Xu (2014) | 1.29 (1.09, 1.60) | 3.60     |
| C. Rizzi (2011) | 1.15 (1.00, 1.31) | 9.60     |
| L. Amundadotin (2009) | 1.10 (1.10, 1.20) | 37.33    |
| E. Dulin (2015) | 1.05 (0.90, 1.23) | 6.46     |
| D. Li (2013) | 1.19 (1.12, 1.27) | 42.61    |
| Overall (I^2 = 0.0%, p = 0.563) | 1.10 (1.13, 1.23) | 100.00   |

B

| Study ID                        | OR (95% CI)   | % Weight |
|---------------------------------|---------------|----------|
| DA. Trégouët-a (2009)           | 1.91 (1.43, 2.54) | 20.01    |
| DA. Trégouët-b (2008)           | 1.77 (1.61, 1.92) | 20.71    |
| DA. Trégouët-c (2009)           | 1.86 (1.64, 1.10) | 19.39    |
| W. Hernandez (2016)             | 1.39 (1.10, 1.80) | 17.44    |
| MP. Riey (2011)                 | 1.19 (1.12, 1.27) | 21.93    |
| Overall (I^2 = 12.8%, p = 0.125) | 1.54 (1.24, 1.92) | 100.00   |

Figure 3
Forest plot of the relationship between rs657152 polymorphisms and cancer (a) and cardiocerebrovascular disease (b) risk (allele model and random-effect model). The circle and horizontal lines correspond to OR and 95% CI and the area of the squares reflects the weight of individual studies included in the meta-analysis. The diamond represents the pooled ORs and 95% CI. The dotted red line represents the total OR value.
Figure 4
Begg's funnel plot of publication bias test for rs505922 and rs657152 (allele model and random-effect model); Each point represents a separate study for the indicated association between rs505922 and cancer (a) and cardiocerebrovascular disease (b), rs657152 and cancer (c) and cardiocerebrovascular disease (d) risk, respectively. Each point stands for an individual article in overall population under allele model. s.e., standardized effect.

Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to download.

ABO-meta-supplemental.doc